Brief: Synact Pharma Announces Positive Interim Phase 2 Data Of AP1189 In Rheumatoid Arthritis

SynAct Pharma AB

09/11/2020 06:33

Nov 9 (Reuters) - SynAct Pharma AB  SYNACT.TE :
    * SYNACT PHARMA ANNOUNCES POSITIVE INTERIM PHASE 2 DATA OF
AP1189
IN RHEUMATOID ARTHRITIS
    * SIGNS OF EFFICACY AGAINST RHEUMATOID ARTHRITIS WAS
OBSERVED
    * DATA ANALYSIS CONDUCTED ON FIRST 26 PATIENTS WHO HAS
COMPLETED
TREATMENT INDICATES THAT AP1189 IS SAFE AND WELL TOLERATED AT
CURRENT DOSE SCHEDULE
    * NUMBER OF PATIENTS CHANGING FROM SEVERE TO MODERATE
CLINICAL
DISEASE ACTIVITY INDEX (CDAI) SCORE WAS HIGHER THAN PLACEBO IN
BOTH TREATMENT GROUPS IN A DOSE DEPENDENT MANNER
    * THERE ARE NO REPORTS OF ANY SERIOUS ADVERSE EVENTS
    * OVERALL FREQUENCY OF ADVERSE EVENTS IS SIMILAR IN TWO
TREATMENT
GROUPS, AND SLIGHTLY HIGHER THAN PLACEBO GROUP
    * SYNACT PHARMA AB - MOST COMMON ADVERSE EVENT WAS NAUSEA

Source text for Eikon:  ID:nWkr9YvkJj 
Further company coverage:  SYNACT.TE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))